In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Medical Device Commercial

Snapshot: April Highlights

  • Analysis

Executive Summary

A selection of articles you may have missed from April 2023, including a deep-dive on the lawsuit between the family of Henrietta Lacks and Thermo Fisher, some concerning figures regarding 'vaccine fatigue' and an interview focusing on the importance of user context in design.

You may also be interested in...



The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.

Execs On The Move: April 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

Swedish Drug And Device To Go Head-To-Head In The GERD Space

Two Swedish companies are working on tackling GERD – one with a drug, one with a device.

Table

View full table

Topics

Tags:
BioPharmaceutical Medical Device Commercial
Latest Headlines

Wave Of New Leaders Could Reshape Generics Industry

Deal-Making In 2023: Pharma Finds Value In Flexibility

Dealmaking Quarterly Statistics, Q1 2023

Fostering a Culture of Innovation, From Evolutionary To Revolutionary

See All
UsernamePublicRestriction

Register

IV147712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By